{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-122076","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.211494+00:00","generated_at":"2026-05-21T01:48:03.680063+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Intellia announces positive two-year Phase 1 data for nex-z in ATTRv-PN with durable TTR reduction","bullets":["Mean serum TTR reduction of 90% by Day 28 remained virtually unchanged for at least 24 months in 33 patients.","14 of 18 patients showed clinically meaningful improvement (≥4 points) on mNIS+7 at 24 months.","5 of 6 patients previously on patisiran and progressing achieved improvement on mNIS+7 at 24 months.","Enrollment progressing well in Phase 3 MAGNITUDE-2 trial for ATTRv-PN; potential BLA submission by 2028.","No new drug-related adverse events; most common were mild-to-moderate infusion reactions with no discontinuations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-122076","json":"https://secwatch.observer/filing/0001193125-25-122076.json","markdown":"https://secwatch.observer/filing/0001193125-25-122076.md","text":"https://secwatch.observer/filing/0001193125-25-122076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525122076/0001193125-25-122076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525122076/d80735d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-21T01:48:03.680063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}